Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restenosis Clear all
Terminated Phase 2Phase 3 Interventional Results available

Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis

NCT00538759
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
External beam radiation therapy, Sham Control
Device · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
75 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

NCT02063672
View directory record Official record
Conditions
Femoral Artery Stenosis, Femoral Artery Occlusion, Restenosis
Interventions
Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
20
States / cities
Fairhope, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 6, 2026, 8:24 AM EDT
Terminated Not applicable Interventional Results available

SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

NCT03474432
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Jesse Brown VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Effects of Paclitaxel on Intimal Hyperplasia

NCT01454778
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Paclitaxel
Drug
Lead sponsor
Patrick Kelly
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

JetStream Atherectomy for the Treatment of In-stent Restenosis

NCT02730234
View directory record Official record
Conditions
Femoropopliteal In-stent Restenosis
Interventions
JetStream XC with balloon angioplasty
Device
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Denver, Colorado • Sebring, Florida • Downers Grove, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 6, 2026, 8:24 AM EDT
Not listed No phase listed Observational

Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System

NCT00852176
View directory record Official record
Conditions
Coronary In-stent Restenosis
Interventions
Not listed
Lead sponsor
Best Vascular, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

NCT01894152
View directory record Official record
Conditions
Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Coronary Restenosis, Myocardial Infarction, Stent Thrombosis, Vascular Disease
Interventions
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 6, 2026, 8:24 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

NCT00001531
View directory record Official record
Conditions
Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 8:24 AM EDT
Not listed Not applicable Interventional

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

NCT01599078
View directory record Official record
Conditions
Restenosis, Peripheral Arterial Disease
Interventions
Paclitaxel, Placebo
Drug
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bettendorf, Iowa
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

NCT02229864
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Coronary artery stenting: Absorb BVS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 6, 2026, 8:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Phase 4 Interventional

SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents

NCT00714545
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis
Interventions
Intracoronary brachytherapy
Radiation
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries

NCT03192696
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Atherectomy Catheter
Device
Lead sponsor
Avinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 6, 2026, 8:24 AM EDT
Withdrawn Phase 2 Interventional

Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

NCT02365415
View directory record Official record
Conditions
Peripheral Pulmonary Stenosis, In-stent Stenosis
Interventions
Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease

NCT00827853
View directory record Official record
Conditions
PERIPHERAL VASCULAR DISEASE
Interventions
Conventional angioplasty balloon, cryoplasty balloon
Procedure
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Davenport, Iowa • Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

In-Stent Restenosis Post-Approval Study

NCT02542267
View directory record Official record
Conditions
Peripheral Artery Disease, Vascular Disease
Interventions
Gore VIABAHN Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Miami, Florida • Honolulu, Hawaii • Rockford, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 6, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 6, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis

NCT01257438
View directory record Official record
Conditions
Restenosis
Interventions
Fluency Plus Endovascular Stent Graft, Percutaneous Transluminal Angioplasty only
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 6, 2026, 8:24 AM EDT
Not listed Phase 2 Interventional

Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis

NCT03106948
View directory record Official record
Conditions
Arteriovenous Fistula Occlusion
Interventions
Placebo, Ascorbic Acid, Cuprimine Oral Product
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 6, 2026, 8:24 AM EDT